IntraBio Inc
Clinical trials sponsored by IntraBio Inc, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Could a simple amino acid ease rare brain disorders? Results expected May 2027 (estimated)
-
Hope for rare brain disease: new drug trial targets movement and daily life
Disease control Recruiting nowThis study tests a drug called N-acetyl-L-leucine (IB1001) in people aged 4 and older with Niemann-Pick disease type C, a rare genetic disorder that affects movement and thinking. The trial compares the drug to a placebo to see if it improves coordination and quality of life. Aft…
Phase 3 • Sponsor: IntraBio Inc • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New hope for rare disease: expanded access to experimental drug for A-T patients
Disease control Expanded accessThis program provides an experimental drug, levacetylleucine, to people with Ataxia-Telangiectasia (A-T), a rare genetic disease that affects movement and immunity. It is for patients who cannot join clinical trials and have no other good treatment options. The goal is to offer p…
Sponsor: IntraBio Inc • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
Could a simple amino acid ease rare brain disorders?
Symptom relief Recruiting nowThis study tests a drug called N-acetyl-L-leucine for people aged 4 and older with CACNA1A gene disorders, which can cause coordination problems, dizziness, and migraines. About 60 participants will receive either the drug or a placebo, then switch, to see if it improves movement…
Phase 3 • Sponsor: IntraBio Inc • Aim: Symptom relief
Last updated Sep 10, 2026 00:00 UTC